Published in Br J Dermatol on August 01, 2008
Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis | NCT02644954
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia (2011) 1.76
Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. Cell Mol Life Sci (2010) 1.20
Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci (2010) 1.06
Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol (2009) 1.04
Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol (2012) 0.99
Identification of a missense variant in LNPEP that confers psoriasis risk. J Invest Dermatol (2013) 0.95
Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol (2014) 0.88
Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years. Postepy Dermatol Alergol (2015) 0.88
Elevated serum heme oxygenase-1 and insulin-like growth factor-1 levels in patients with Henoch-Schonlein purpura. Rheumatol Int (2009) 0.87
Comorbidities and cardiovascular risk factors in patients with psoriasis. An Bras Dermatol (2014) 0.85
Cardiovascular comorbiditiy in psoriasis. Indian J Dermatol (2011) 0.83
Macrophage Heterogeneity and Plasticity: Impact of Macrophage Biomarkers on Atherosclerosis. Scientifica (Cairo) (2015) 0.79
Diet and dermatology: the role of dietary intervention in skin disease. J Clin Aesthet Dermatol (2014) 0.76
Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract (2013) 0.75
Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis. Int J Clin Rheumtol (2015) 0.75